DaVita Inc.
DVA
Classificação em ações
#1794
DaVita Inc. specializes in delivering essential kidney dialysis treatments and... DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Preço da ação
$187.20
Última sincronização: 2026-10-19
Valor de mercado
$11.94B
Variação (1 dia)
0.21%
Variação (1 ano)
46.19%
País
US
Negociar DaVita Inc. (DVA)
Categoria
Healthcare
Rácio P/E de DaVita Inc. (DVA)
Rácio P/E em October 2026 TTM: 15.54
De acordo com os últimos relatórios financeiros e o preço das ações da DaVita Inc., o rácio P/E atual (TTM) é 15.54. No final de 2024, a empresa tinha um P/E de 13.57.
Histórico do rácio P/E da DaVita Inc. de 2000 a 2026
Rácio P/E no final de cada ano
| Ano | Índice P/E | Alterar |
|---|---|---|
| 2026 (TTM) | 15.54 | 15.69% |
| 2025 | 13.43 | -1.10% |
| 2024 | 13.57 | -1.30% |
| 2023 | 13.75 | 11.00% |
| 2022 | 12.39 | 1.28% |
| 2021 | 12.23 | -32.70% |
| 2020 | 18.18 | 28.28% |
| 2019 | 14.17 | -74.30% |
| 2018 | 55.14 | 168.49% |
| 2017 | 20.54 | 39.58% |
| 2016 | 14.71 | -73.13% |
| 2015 | 54.76 | 146.24% |
| 2014 | 22.24 | 5.88% |
| 2013 | 21.00 | 6.08% |
| 2012 | 19.80 | 31.89% |
| 2011 | 15.01 | -13.66% |
| 2010 | 17.39 | 20.76% |
| 2009 | 14.40 | 3.35% |
| 2008 | 13.93 | -10.87% |
| 2007 | 15.63 | -23.10% |
| 2006 | 20.33 | -8.92% |
| 2005 | 22.32 | 27.09% |
| 2004 | 17.56 | 25.84% |
| 2003 | 13.95 | 23.89% |
| 2002 | 11.26 | -24.48% |
| 2001 | 14.92 | -85.60% |
| 2000 | 103.60 | 0.00% |
Rácio P/E para empresas semelhantes ou concorrentes
| Empresa | Rácio P/E | Diferença do rácio P/E | País |
|---|---|---|---|
| 15.70 | 1.06% |
US
|
|
| - | - |
DE
|
|
| 10.40 | -33.08% |
US
|
|
| 32.07 | 106.40% |
SA
|
|
| 20.00 | 28.72% |
BR
|
Como interpretar um P/E Ratio?
O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.
Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.
Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.